How do I know whether my compounded medication was recalled?

A recall applies when the dispensing pharmacy or company, medication and lot number on the label match the notice. Strength, dosage form, package size and expiration date can provide extra confirmation. FDA posts public drug recall announcements, but not every recall is publicly announced, so the pharmacy named on the prescription label is an essential second check.

What should I do if my lot number matches a recall?

The instructions in the specific recall notice should guide the response. They may say to stop using the medication, keep it separate and contact the dispensing pharmacy about return or disposal. The prescriber should be told about symptoms or treatment questions. Severe symptoms such as trouble breathing, fainting, confusion or signs of shock need emergency help.

What does a patient-level drug recall mean?

A patient-level recall is intended to reach the people who received the medication, rather than stopping with a wholesaler, hospital or pharmacy. In the August 5 glutathione recall, the pharmacy said it was notifying both patients and prescribers by phone and mail and arranging retrieval and proper disposal of the affected vials.

Who contacts me about a compounded drug recall?

The dispensing pharmacy, prescriber or manufacturer may make contact, while FDA posts many public notices and oversees recall strategy. For a patient-specific compounded prescription, the pharmacy's dispensing record can connect the patient to a medication lot. That is why the pharmacy name and contact information on the label are worth keeping with the vial.

Was compounded semaglutide included in the August 2026 glutathione recall?

No. The August 5 recall covered three lots of compounded glutathione 200 mg/mL from Victory Medical Center Pharmacy. It did not name semaglutide, tirzepatide or a Promise medication. A recall of one preparation should not be expanded to every medication made by compounding pharmacies; the product, source and lot all matter.

What is bacterial endotoxin?

Bacterial endotoxin is material from the outer wall of certain bacteria that can trigger a strong immune reaction. Excessive levels in an injection may cause fever, chills, headache, nausea, vomiting, low blood pressure or shock. Endotoxin can remain even without live bacteria, which is why sterile products also need controls aimed specifically at endotoxin.

Compounded Medication Recall: Check the Lot

A compounded medication recall is specific. The pharmacy name, medication and lot number on the label all have to match the notice. If they do, the medication stays set aside while the dispensing pharmacy and prescriber explain what happens next. If they don't, that notice isn't about that vial.

That distinction matters after an August recall involving compounded glutathione. It did not involve semaglutide, tirzepatide or a Promise medication. It did show why having a pharmacy of record—the pharmacy named on the prescription label—matters when a problem is found.

What happened in the August 5 recall

On August 5, 2026, Victory Medical Center Pharmacy in Austin recalled three lots of compounded glutathione 200 mg/mL multi-dose vials after its testing found elevated bacterial endotoxin. Endotoxin is material from certain bacteria that can set off a sudden, dangerous immune reaction even when live bacteria aren't found.

The affected lot numbers were 1980571, 1981940 and 1984345. The pharmacy said the vials had gone to patients in Texas, Florida and New York. It was a patient-level recall, meaning the notification was meant to reach the people who had received the medication, not stop at a wholesaler or clinic. The pharmacy said it was contacting prescribers and patients by telephone and mail.

Reported reactions included fever, chills, severe headache, nausea, vomiting, rapid heartbeat, blood-pressure changes, body aches and injection-site reactions. Those reports were signals tied to the affected product; they don't mean every person with one of those symptoms had endotoxin exposure.

As of September 6, 2026, the day this article was written, FDA's August 27 investigation update said at least 30 patients had reported adverse events after IV (into a vein) glutathione from different pharmacies, some requiring hospitalization. FDA connected the preparations to ingredient lot 229536, said two Texas pharmacies had recalled glutathione injections for elevated endotoxin, and said the investigation was continuing.

How to check a compounded medication recall

The label and the recall notice should be compared in three places. A drug name alone isn't enough.

What to match	Why it matters
Dispensing pharmacy or company	Two pharmacies can compound the same ingredient without sharing a recall
Medication, strength and form	A recall may cover an injection but not another preparation
Lot number	A lot is one traceable production batch; recalls often cover only named batches

The expiration date and package size can provide a fourth check when the notice lists them. The FDA drug recall page collects public announcements, while FDA's enforcement reports include all drug recalls monitored by the agency. FDA also notes that not every recall receives a public announcement, so the dispensing pharmacy remains an important source.

When all the details match, the instructions in that specific notice control. In the Victory notice, affected patients were told to stop using the vial, keep it separate and contact the pharmacy for return and proper disposal. A prescriber should hear about any symptoms. Trouble breathing, fainting, confusion or signs of shock call for emergency help.

Who contacts the patient, and why lots matter

Drug recalls are often voluntary actions started by the company. FDA oversees how the recall is carried out and checks whether customers were notified and the product was removed. In a patient-level pharmacy recall, the dispensing record connects a name and prescription to the affected lot. That is how a general warning becomes a direct phone call or letter.

The value of that trail is not theoretical. A 2018 report in Epidemiology & Infection described seven cases of probable endotoxin poisoning linked to compounded glutathione. In a separate hospital investigation, seven patients developed bloodstream infections after receiving compounded fentanyl; taking the preparation out of use ended the outbreak, and testing eventually found the organism in a single lot (Moehring et al., JAMA Internal Medicine, 2014).

A lot number doesn't prevent a quality problem. It gives the pharmacy, prescriber and regulators a way to find the right vials and the right patients quickly.

What this recall does—and does not—mean

This was a glutathione recall. It was not a recall of compounded semaglutide or tirzepatide, and it was not a finding about every compounded medication. Recalls answer a narrow question: which product, from which source, in which batches needs to be removed or corrected?

The broader context still deserves plain language. FDA does not check a compounded drug's safety, effectiveness or quality before it reaches the market. Compounded medications can meet needs that a standard manufactured product cannot, but poor compounding can lead to contamination or the wrong strength. How compounded medications are made explains that process without the regulatory shorthand.

Promise's semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation when it is appropriate; that decision is between the patient and the doctor. The same product distinction is covered on the pages for compounded semaglutide and compounded tirzepatide.

Why a pharmacy of record changes the answer

A grey-market vial bought from an anonymous seller can vanish from a listing, but it cannot move through the same patient-level recall chain. There may be no licensed dispensing pharmacy, patient record or reliable distribution list connecting a batch to the people holding it. A printed lot number is of little help when no accountable source can trace where that lot went.

A prescription route creates people to contact: the dispensing pharmacy about the product and lot, and the prescriber about symptoms and the treatment plan. It does not make recalls impossible. It makes a response possible.

At Promise, a licensed provider reviews every request and not everyone qualifies. When a prescription is written, a licensed U.S. compounding pharmacy dispenses the medication.

What to watch next

FDA said on August 27 that its glutathione investigation was active and that it would post updates. Someone holding compounded glutathione from the affected period needs the exact pharmacy and lot, not a guess based on the ingredient name. For any compounded medication, a new symptom or suspected quality problem can also be reported through FDA MedWatch, alongside contacting the prescriber and dispensing pharmacy.

The calm way through a recall is a short chain: read the notice, match the label, keep the product separate, and call the people named on the prescription.